Your patient’s brain may be undermining their weight-loss efforts1

Powerful cravings and insatiable hunger can make it difficult for patients to control their eating1,2

A 3D image of a purple brain with a green circle highlighting the hypothalamus. The line on the left is connected to copy that reads <q>Mesolimbic Reward System</q> and the line on the right reads <q>Hypothalamus. </q>

Mysimba® targets 2 areas of the brain to give patients more control of their eating1,5*

  • Within the mesolimbic reward system, naltrexone and bupropion regulate feelings of pleasure when eating to help control cravings
  • In the hypothalamus, bupropion and naltrexone work synergistically to curb hunger

*The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.5

View study results
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

References:

  1. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196.
  2. Reichelt AC, Westbrook RF, Morris MJ. Integration of reward signalling and appetite regulating peptide systems in the control of food-cue responses. Br J Pharmacol. 2015;172(22):5225-5238.
  3. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013;14(1):2-18.
  4. Pelchat ML. Of human bondage: food craving, obsession, compulsion, and addiction. Physiol Behav. 2002;76(3):347-352.
  5. Mysimba® (naltrexone HCl and bupropion HCl) Summary of Product Characteristics (SmPC).